What issues has DexCom faced in the past year?

DexCom, a medical device company, has faced a series of issues in the past year, including an FDA warning letter over unapproved changes to its CGM devices, a Class 1 recall for some of its receivers, and several class-action lawsuits claiming false advertising and device malfunctions.

How has DexCom's stock price been affected?

DexCom's stock price has declined by 20% over the trailing-12-month period and is barely above its 52-week low.

What is the outlook for DexCom according to Wall Street analysts?

Despite the challenges, Wall Street analysts remain bullish on DexCom, with an average price target of $87, representing a potential upside of around 58% from the company's current levels.

Home / Business and Economy / DexCom Faces Regulatory Woes, Analysts Bullish on Comeback

DexCom Faces Regulatory Woes, Analysts Bullish on Comeback

13 Nov

•

Summary

DexCom's stock price down 20% in past year
FDA warning letter over unapproved device changes
Class 1 recall for some CGM receivers
Lawsuits claim false advertising, device malfunctions

DexCom Faces Regulatory Woes, Analysts Bullish on Comeback

As of November 13, 2025, DexCom (NASDAQ: DXCM), a leading medical device company specializing in continuous glucose monitoring (CGM) systems for diabetes patients, has been grappling with a series of issues that have weighed heavily on its stock price. Over the past 12 months, the company's shares have declined by 20% and are barely above their 52-week low.

Despite these challenges, Wall Street analysts remain optimistic about DexCom's prospects. The company's average price target of $87, according to Yahoo! Finance, represents a potential upside of around 58% from its current levels. Analysts believe that DexCom can overcome its recent setbacks and stage a turnaround.

The company's troubles began last year with the rollout of its latest CGM device, the G7, which led to higher-than-expected rebate eligibility, resulting in lower revenue per user and overall top-line growth. This temporary issue contributed to DexCom's worse-than-expected financial results in 2024.